Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRAS Peptide Vaccine + Nivolumab + Ipilimumab in Resected MMR-p Colorectal and Pancreatic Cancer
NCT04117087Phase 1Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2020
- Primary completion
- Jun 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of TG01 in colorectal cancer (CRC) and pancreatic cancer (PC) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Number of participants experiencing study drug-related toxicities at 2 years and Fold change in interferon-producing mutant-KRAS-specific cytotoxic (CD8) and helper (CD4) T cells at 16 weeks. Started May 2020; status: active, not recruiting.
02
Drugs
TG01
03
Conditions
colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04117087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04117087.